2018
DOI: 10.1177/1074248418786936
|View full text |Cite
|
Sign up to set email alerts
|

Does Ticagrelor Improve Endothelial Function?

Abstract: Ticagrelor is a P2Y receptor antagonist with proven clinical benefit in patients with acute coronary syndrome. Apart from its principal antiplatelet action, pleiotropic effects have been implicated in the clinical profile of ticagrelor, including a potentially beneficial impact on endothelial function. In light of the common presence and prognostic value of endothelial dysfunction in patients with coronary artery disease, several clinical studies have investigated the postulated effect of ticagrelor on endothe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 38 publications
(36 reference statements)
0
11
0
Order By: Relevance
“…Our study, in which the P2Y12 antagonist was administered in vivo and myocardial infarct subsequently induced ex vivo, in the absence of platelets, definitively confirms that the protective effect is mainly due to a preconditioning effect in vivo that lasts throughout the IR procedure ex vivo. The lack of cardioprotection by Ticagrelor when administered in the ex vivo model further support the idea of a blood cell-mediated preconditioning effect [5,8,31]. Given the apparent dependence upon the presence of blood in mediating Ticagrelor effects [5,17], it would seem logical to propose that the cardioprotective effect of Ticagrelor is dependent on platelets and likely the P2Y12 receptor.…”
Section: Oxidative Medicine and Cellular Longevitymentioning
confidence: 64%
See 1 more Smart Citation
“…Our study, in which the P2Y12 antagonist was administered in vivo and myocardial infarct subsequently induced ex vivo, in the absence of platelets, definitively confirms that the protective effect is mainly due to a preconditioning effect in vivo that lasts throughout the IR procedure ex vivo. The lack of cardioprotection by Ticagrelor when administered in the ex vivo model further support the idea of a blood cell-mediated preconditioning effect [5,8,31]. Given the apparent dependence upon the presence of blood in mediating Ticagrelor effects [5,17], it would seem logical to propose that the cardioprotective effect of Ticagrelor is dependent on platelets and likely the P2Y12 receptor.…”
Section: Oxidative Medicine and Cellular Longevitymentioning
confidence: 64%
“…Ticagrelor was dissolved at 3.70 μ M concentration in Krebs solution. The in vivo dose of Ticagrelor and the in vitro concentrations of both Ticagrelor and INF were chosen according to previous studies demonstrating their efficacy against myocardial IR injury [ 13 , 24 , 28 , 31 ].…”
Section: Methodsmentioning
confidence: 99%
“…The biologic effects of adenosine on ameliorating endothelial dysfunction are well established. 4,9,24 In addition, ticagrelor was found to block the contractile effect of adenosine diphosphate in the vascular smooth muscle that expresses P2Y 12 receptors. 25 In humans, a loading dose of ticagrelor 180 mg increased the plasma adenosine concentration in patients with ACS compared to a loading dose of clopidogrel 600 mg. 5 A loading dose of ticagrelor 180 mg also enhanced adenosine-induced coronary blood flow velocity in healthy volunteers 6 and in patients with NSTE-ACS.…”
Section: Discussionmentioning
confidence: 99%
“…[16][17][18] Peripheral arterial tonometry and baFMD provide distinct information regarding vascular function, and baFMD is the most established and commonly used method, although baFMD is more technically difficult. 9,19 However, until now, only 2 prior studies have evaluated the effect of ticagrelor on endothelial dysfunction using baFMD. One study evaluated patients with stable CAD but did not enroll patients with prior ACS, 11 while the other enrolled patients with ACS with type 2 diabetes in the acute period.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation